FGF9 Alleviates the Fatty Liver Phenotype by Regulating Hepatic Lipid Metabolism

Fanrong Zhao 1†, Lei Zhang 1†, Menglin Zhang 1, Jincan Huang 1, Jun Zhang 2* and Yongsheng Chang 1*

1Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Key of Cellular Homeostasis and Disease, Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China, 2Department of Basic Medicine, School of Medicine, Shihezi University, Shihezi, China

Although the fatty liver has been linked to numerous impairments of energy homeostasis, the molecular mechanism responsible for fatty liver development remains largely unknown. In the present study, we show that fibroblast growth factors 9 (FGF9) expression is increased in the liver of diet-induced obese (DIO), db/db, and ob/ob mice relative to their respective controls. The long-term knockdown of hepatic FGF9 expression mediated by adeno-associated virus expressing FGF9-specific short hairpin RNA (AAV-shFGF9) aggravated the fatty liver phenotype of DIO mice. Consistently, downregulation of FGF9 expression mediated by adenovirus expressing FGF9-specific shRNA (Ad-shFGF9) in the primary hepatocyte promoted the cellular lipid accumulation, suggesting that FGF9 exerts its effects in an autocrine manner. In contrast, adenoviruses expressing FGF9 (Ad-FGF9) mediated FGF9 overexpression in the liver of DIO mice alleviated hepatic steatosis and improved the insulin sensitivity and glucose intolerance. Moreover, the liver-specific FGF9 transgenic mice phenocopied the Ad-FGF9-infected mice. Mechanistically, FGF9 inhibited the expression of genes involved in lipogenesis and increased the expression of genes involved in fatty acid oxidation, thereby reducing cellular lipid accumulation. Thus, targeting FGF9 might be exploited to treat nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome.

Keywords: lipid synthesis, fatty acid oxidation, lipogenesis, fatty liver, FGF9

INTRODUCTION

The liver is a central metabolic organ that regulates hepatic lipid metabolism, including lipogenesis, fatty acid oxidation, and lipoprotein uptake and secretion (Browning and Horton, 2004). The excessive accumulation of triglycerides (TGs) in hepatocytes is the hallmark of NAFLD. The spectrum of NAFLD ranges from simple fatty liver (hepatic steatosis) to nonalcoholic steatohepatitis (NASH), which may lead to liver fibrosis and cirrhosis, resulting in increased morbidity and mortality (Brunt, 2010). NAFLD is closely associated with insulin resistance, obesity, and other metabolic diseases (Browning and Horton, 2004). Although the fatty liver has been attributed to abnormal energy metabolism, the molecular mechanisms underlying fatty liver development remain largely unknown.

De novo lipogenesis is remarkably induced in NAFLD patients, contributing to the excessive TG accumulation in the liver. Moreover, hepatic lipogenesis, which is normally inhibited in the fasting
state, is relatively high under fasting conditions and fails to further increase after feeding in NAFLD patients (Diraison et al., 2003; Donnelly et al., 2005). Carbohydrate response element-binding protein (ChREBP) is a basic helix-loop-helix leucine-zipper transcription factor, which is highly expressed in the liver and has been shown to regulate hepatic lipogenesis via activating its target genes, including fatty acid synthase (FAS), acetyl-CoA carboxylase 1 (ACC1), and stearoyl-CoA desaturase 1 (SCD1) (Jois and Sleeman, 2017). The liver-specific knockout of ChREBP in ob/ob mice improved hepatic steatosis and insulin resistance (Dentin et al., 2006). In contrast, overexpression of ChREBP in the liver of mice resulted in worsening of hepatic steatosis (Benhamed et al., 2012). These studies clearly suggest that ChREBP is a key mediator of hepatic steatosis.

Peroxisome proliferator-activated receptor γ (PPARγ) belongs to the nuclear receptor superfamily, which is highly expressed in adipose and required for the differentiation of preadipocytes to mature adipocytes. PPARγ is typically expressed in the liver at only 20% of the levels found in adipose tissue (Tontonoz et al., 1994). However, PPARγ expression is markedly induced in the severe fatty liver. Hepatic PPARγ deficiency remarkably alleviates the fatty liver phenotype (Matsue et al., 2003), clearly indicating that PPARγ is capable of activating the expression of genes involved in TG accumulation in hepatocytes and promoting the development of fatty liver. However, PPARα, another member of the PPAR subfamily, stimulates fatty acid oxidation and improves lipoprotein metabolism by regulating the expression of genes involved in peroxisomal and mitochondrial β-oxidation pathways, fatty acid uptake, and triglyceride catabolism. Mice lacking PPARα accumulate a copious amount of hepatic TG and become hypoketonic and hypoglycemic during fasting (Leone et al., 1999). Fibrates, the synthetic PPARα agonists, have been used to treat dyslipidemia (Lefebvre et al., 2006).

The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes and physiological functions (Beenken and Mohammadi, 2009). In mammals, 18 members of the FGF family are divided into two categories, namely, endocrine and paracrine. The FGF19, FGF21, and FGF23 subfamilies have been shown to function in an endocrine manner, dependent on the presence of Klotho proteins in their target tissues, to regulate glucose, bile acid, vitamin D, and phosphate homeostasis, while other members of the FGF family are considered paracrine factors and are known for their roles in tissue patterning and organogenesis during embryogenesis (Degirolamo et al., 2016). Previous studies suggest that FGF9 participates in palatine, sex determination, and lung development (Colvin et al., 2001; Yin et al., 2011; Iwata et al., 2012). Interestingly, recently two studies showed that FGF9 regulates browning of white adipocytes and is associated with human obesity (Sun et al., 2019; Shamsi et al., 2020). However, the physiological role of FGF9 in other metabolically active tissues remains unexplored. In the present study, we show that fasting-induced FGF9 in the liver regulates hepatic lipid metabolism in a cell-autonomous manner. Targeting FGF9 signaling might be exploited to treat NAFLD and other metabolic diseases.

RESULTS

The Expression of FGF9 is Dysregulated in the Liver of Mice With Hepatic Steatosis

FGF21 is a peptide hormone, secreted predominantly from the liver, and its expression is increased in the fasting state (Badman et al., 2007; Inagaki et al., 2007). FGF21 has been shown to regulate the metabolism of lipids and glucose, and FGF21 agonism holds significant potential for treatment of NASH (Ritchie et al., 2020).

To identify a novel secreted protein regulating systemic glucose and lipid metabolism, we have previously performed microarray analysis of livers of mice with hepatic steatosis (Shen et al., 2014). Preliminary data suggest that mRNA levels of FGF9, another member of FGF family, are also increased in the liver of ob/ob mice. Our real-time PCR and Western blotting data confirmed the microarray analysis (Figures 1A,B). We obtained similar results in DIO mice (Figures 1C,D). Interestingly, similar to FGF21, fasting-induced hepatic FGF9 expression, while refeeding, reversed this effect (Figures 1E,F).

These results indicate that FGF9 expression is regulated by different nutritional status, and FGF9 might have an important effect on hepatic glucose and lipid metabolism.

Knockdown of FGF9 by AAV-shFGF9 in the Liver of DIO Mice Aggravated Hepatic Steatosis

Given that FGF9 expression is induced in the liver of DIO mice, we explored the effects of long-term hepatic FGF9 deficiency on systemic metabolism. We first generated an adeno-associated virus expressing FGF9-specific short hairpin RNA (AAV-shFGF9) and infused AAV-shFGF9 into mice via the tail vein. Feeding a chow diet or high-fat diet after eight weeks, the mice were sacrificed for further studies. As a result, the knockdown of FGF9 did not affect hepatic lipid metabolism or systemic glucose metabolism in mice fed with a chow diet (Supplementary Figures S1B–E). However, an increased liver-to-body weight ratio was observed in mice injected with AAV-shFGF9 (Figure 2A). Moreover, AAV-shFGF9 treatment further aggravated glucose intolerance and insulin resistance induced by HFD (Figures 2B,C), and impaired hepatic insulin signaling (Figure 2D). Furthermore, H&E and Oil Red O staining revealed lipid accumulation in the liver (Figure 2E). The biochemical analysis also confirmed the significant increase in hepatic TG levels in AAV-shFGF9-injected mice (Figure 2F).

We also explored the molecular mechanism for the aggravated fatty liver phenotype in AAV-shFGF9-injected mice. We found that FGF9 knockdown in the liver increased the expression of genes involved in lipid synthesis (ChREBP, Fasn, and PPARγ) and fatty acid transport (Fabp1, Fabp4, and CD36). Meanwhile, AAV-shFGF9 treatment also decreased the expression of genes involved in lipid oxidation (Cpt1a, Cyp4a10, and Cyp4a14),
as shown in Figures 2G,H. The results suggest that FGF9 plays an important role in the hepatic lipid metabolism.

**Knockdown of FGF9 Expression in Primary Hepatocyte Increased Cellular Triglyceride Contents**

We next studied whether the effect of FGF9 deficiency on hepatic lipid metabolism is cell autonomous. We generated an adenovirus expressing FGF9-specific shRNA (Ad-shFGF9) and controlled adenovirus Ad-shCon. Primary hepatocytes treated with OA&PA, which stimulates cellular lipid synthesis, were infected with Ad-shFGF9 to observe the short-term effects of FGF9 deficiency on cellular lipid metabolism. As a result, the knockdown of FGF9 expression in primary hepatocytes increased lipid accumulation, as shown in Figures 3A,B.

Consistent with the aforementioned data obtained in DIO mice, we found that Ad-shFGF9 treatment increased the expression of several genes involved in lipogenesis such as ChREBP, Fasn, and PPARγ in primary hepatocytes. The expression of lipid-coated proteins such as cidea and plin2 was also increased. However, the expression of genes related to fatty acid oxidation such as Cpt1a, CYP4a10, and Cyp4a14 was down-regulated in primary hepatocytes infected with Ad-shFGF9. The Western blotting analysis confirmed real-time PCR results, as shown in Figures 3C,D. These results suggested that FGF9 regulating hepatic lipid metabolism is a cell-autonomous effect and FGF9 acts as an autocrine factor.

**Overexpression of FGF9 Mediated by Adenovirus in Primary Hepatocyte Reduced Cellular Lipid Contents**

Given that FGF9 knockdown increased cellular lipid accumulation, we next explored whether an increased expression of FGF9 in hepatocytes can reduce cellular lipid contents. To this end, the primary hepatocytes were infected with either Ad-FGF9 or Ad-GFP and followed by treatment with palmitic acid and oleic acid (OA&PA). As expected, cellular lipid accumulation induced by OA&PA was suppressed by Ad-FGF9 treatment (Figures 4A,B).

Correspondingly, Ad-FGF9 treatment decreased the expression of several genes involved in lipogenesis such as ChREBP, Fasn, and PPARγ, and fatty acid transport, including CD36, in primary hepatocytes, whereas it increased the expression of genes related to fatty acid oxidation such as Cpt1a, CYP4A10, and Cyp4a14.
Meanwhile, the Western blotting analysis further confirmed these results (Figure 4D). The results suggested that the overexpression of FGF9 in primary hepatocyte reduced cellular lipid accumulation induced by OA&PA.

### Adenovirus-Mediated FGF9 Overexpression in the Liver of Diet-Induced Obese Mice Alleviates Hepatic Steatosis

To further explore the effect of FGF9 overexpression on hepatic lipid metabolism, we injected Ad-FGF9 or Ad-GFP (as a control) into chow or high-fat diet-fed C57BL/6J mice via the tail vein. As shown in Supplementary Figure S2, FGF9 overexpression in chow diet-fed mice did not significantly influence the systemic glucose metabolism or hepatic lipid metabolism.

However, the injection of Ad-FGF9 into DIO mice decreased the ratio of liver weight to body weight (Figure 5A). In contrast to the results obtained in AAV-shFGF9-infected DIO mice, Ad-FGF9 injection improves glucose intolerance as revealed by GTT experiments (Figure 5B), and enhanced insulin sensitivity, as revealed by...
ITT experiments (Figure 5C), and enhanced hepatic insulin signaling (Figure 5D). Notably, histological analysis of liver sections (H&E and Oil Red O staining) indicated that the fatty liver phenotype was markedly alleviated in DIO mice injected with Ad-FGF9 (Figure 5E). The biochemical analysis confirmed the reduced hepatic triglyceride content in Ad-FGF9-treated DIO mice (Figure 5F). At the same time, the decreased ALT and AST levels in DIO mice injected with Ad-FGF9 indicate that the overexpression of FGF9 alleviated the liver injury induced by HFD (Figures 5G,H).

Consistent with the results obtained in vitro, Western blotting and real-time PCR analysis confirmed that FGF9 overexpression in the liver of DIO mice inhibited the expression of genes involved in lipogenesis and increased the expression of genes related to fatty acid oxidation (Figures 5I,J). These results clearly suggest that FGF9 regulates the hepatic lipid metabolisms in DIO mice.

Liver-Specific FGF9 Transgenic Mice Protected Against Hepatic Steatosis and Insulin Resistance Induced by HFD

To further confirm whether the overexpression of FGF9 inhibits NAFLD development induced by HFD, we generated liver-specific FGF9 transgenic mice (FGF9^{alb-cre}) by crossing Alb-Cre mice and FGF9 Rosa26 knockin mice. Alb-Cre mice express the Cre-recombinant gene under the control of the albumin gene promoter. The FGF9 Rosa26 knockin mice were generated by the insertion of FGF9 cDNA downstream of the Rosa26 promoter and a loxP-stop-loxP cassette. The Western blotting analysis confirmed the FGF9 overexpression in the liver of FGF9^{alb-cre} (Figure 6A). FGF9 Rosa26 knockin mice were used as control mice. Again, when mice were fed a chow diet, FGF9 transgene in the liver did not affect markedly the systemic glucose metabolism and hepatic lipid metabolism (Supplementary Figure S3). However, when mice were fed...
a high-fat diet, we observed that the ratio of liver weight to body weight in FGF9<sub>alb-cre</sub> mice was lower than that of control mice (Figure 6B). Moreover, FGF9 transgene enhanced the insulin sensitivity and improved glucose intolerance in diet-induced obese FGF9<sub>alb-cre</sub> mice when compared to the control mice (Figures 6C–E). Furthermore, lipid accumulation in the liver was reduced from FGF9<sub>alb-cre</sub> mice, as revealed by H&E and Oil Red O staining analysis (Figure 6F), and biochemical analysis (Figure 6G). Consistently, FGF9 transgene decreased the levels of serum ALT and AST, further confirming that the overexpression of FGF9 can alleviate the liver injury induced by HFD (Figure 6H).

We also examined the expression of genes involved in lipid metabolism in the liver of FGF9 transgenic mice. Western blotting and real-time PCR data further confirmed that FGF9 transgene inhibited the expression of lipogenic genes, while it enhanced the expression of genes related to fatty acid oxidation (Figures 6I,J). Collectively, these results clearly suggested that liver-specific FGF9 transgenic mice were resistant to HFD-induced NAFLD.

**DISCUSSION**

Given the rising incidence and high prevalence of NAFLD, the absence of approved therapies is striking. Currently, lifestyle changes, weight loss, and exercise are the main treatments available to modify the disease process. Thus, there is an urgent need of new drugs for treatment of NAFLD and NASH (Tiniakos et al., 2010; Rotman and Sanyal, 2017).

Previous studies indicated that FGF9 is involved in multiple developmental processes (Colvin et al., 2001; Yin et al., 2011; Iwata et al., 2012). Recently two studies showed that FGF9 regulates browning of white adipocytes and is associated with human obesity (Sun et al., 2019; Shamsi et al., 2020). Sun et al. (2019) reported that FGF9 expression in adipose tissue is reduced upon cold exposure and FGF9 treatment inhibited browning of white adipocytes. However, Shamsi et al. reported that cold exposure induces FGF9 expression in adipose tissues and FGF9 strongly induced UCP1 expression in adipocytes and preadipocytes, which is independent of adipogenesis and involves the FGFR3-PGE2-EP2/4 signaling pathway. Thus, it appears that FGF9 exerts its metabolic effects in an autocrine manner.
In the present study, we showed that hepatic FGF9 expression is upregulated in mice with the fatty liver, including HFD-induced obese and ob/ob mice relative to their respective control mice. Of note, we detected the two bands of FGF9 protein in livers of DIO mice, as revealed by Western blotting analysis, possibly due to the alternate splicing of FGF9 mRNA in DIO mice or different antibodies we used to detect an unspecific protein. Currently, two bands of FGF9 in nature remain unclear. Moreover, fasting also induces FGF9 expression in the mouse liver. Furthermore, FGF9 knockdown in the primary hepatocyte treated with OA and PA increased cellular lipid accumulation. Consistently, FGF9 knockdown in the liver of HFD-induced obese mice aggravated the symptoms of hepatic steatosis. These data suggest that FGF9 regulates hepatic lipid metabolism in an autocrine manner, as that observed in adipose tissues (Sun et al., 2019; Shamsi et al., 2020). Notably, FGF9 knockdown in the liver of chow diet-fed mice did not significantly change hepatic TG contents, indicating FGF9 exerts its effects in the context of high-fat stress. FGF9 expression is induced in the liver of both DIO mice and ob/ob mice. The overexpression of FGF9 in the liver of DIO mice improved insulin sensitivity and fatty liver phenotype. Whether FGF9 has same effects in ob/ob mice remains unexplored. Additionally, although our study shows that FGF9 regulates hepatic triglycerides contents in DIO mice, we did not characterize the lipid species influenced by FGF9. Ceramides are the best studied sphingolipids in relation to insulin resistance (Meikle and Summers, 2017). Thus, whether and how FGF9 influences ceramides contents deserve further study.

Multiple factors contribute to fatty liver development. Increased TG accumulation in the liver reflects an input/output imbalance of hepatic FFA metabolism. An increase in
FFA delivery to the liver due to adipose tissue insulin resistance, and de novo lipogenesis driven by the hyperinsulinemia might cause fatty liver disease (Rotman and Sanyal, 2017). In contrast, the decrease in VLDL secretion or fatty acid β-oxidation also induces the fatty liver phenotype (Fabbrini et al., 2008; Zhang et al., 2013). In the present study, we found that FGF9 regulates hepatic lipid metabolism with several distinct mechanisms. FGF9 inhibits cellular lipid synthesis by repressing the expression of ChREBP, Fasn, and PPARγ, while it enhances fatty acid oxidation by inducing target genes of PPARα, including Cpt1a, Cyp4a11, and Cyp4a14. Of note, FGF9 did not influence the protein levels of PPARα (data not shown). We speculated that FGF9 might enhance PPARα transcriptional activity via posttranslational modification (Hinds et al., 2016) or increase the contents of its endogenous ligands. In addition, how FGF9 represses the expression of ChREBP and PPARγ remains unclear. Further studies are required to clarify this question.

FGF21, another member of FGF family, acting as an endocrine factor, is also induced directly by PPARα in the mouse liver in response to fasting and PPARα agonists. Induced FGF21, in turn, stimulates fatty acid oxidation and ketogenesis in the liver (Badman et al., 2007; Inagaki et al., 2007). Moreover, the adenoviral knockdown of FGF21 in the liver of mice fed a high-fat, low carbohydrate ketogenic diet (KD) caused the fatty liver and reduced serum ketones (Badman et al., 2007). Furthermore, injection of recombinant FGF21 proteins into DIO
mice reversed hepatic steatosis due to FGF21 inhibition of hepatic lipogenesis (Xu et al., 2009). Our study indicates that FGF9 regulates hepatic lipid metabolism in an autocrine manner. Thus, FGF9 regulates hepatic lipid metabolism with similar mechanisms as FGF21. Fasting-induced FGF9 promotes hepatic fatty acid oxidation; meanwhile, it also inhibits hepatic lipogenesis, thereby improving the fatty liver phenotype.

NAFLD is the hepatic manifestation of the metabolic syndrome and becoming increasingly common with the rising incidence of obesity, diabetes, hyperlipidemia, and cardiovascular disease worldwide. Thus, the treatment of fatty liver should exhibit wider systemic effects and fit into a larger treatment of the syndrome (Ritchie et al., 2020). Our results suggest the beneficial effect of FGF9 on NAFLD, and targeting the FGF9 signaling pathway might be exploited to treat NAFLD or NASH. Of note, FGF9 has potential mitogenic activity (Tsai et al., 2002), which may lead to safety concerns. Fortunately, Shamsi et al. (2020) generated a modified FGF9 protein carrying K168Q/R173V/R177Q triple mutations in its HS-binding sites. This mutant reduced the molecule’s mitogenic potential without impacting its metabolic function. Thus, this FGF9 mutant might have potential for treatment of NAFLD.

MATERIALS AND METHODS

Animal Treatment

Male C57BL/6j, ob/ob, db/db, and db/m mice at 8 weeks of age were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China) and housed and maintained in 12 h light and dark photoperiods with a regular unrestricted diet.

For adeno-virus infection, 8-week-old male C57BL/6j mice were fed a chow diet or HFD (D12492, Jiangsu Xietong Bio-engineering Co., Ltd., China) for 3 months, followed by infection with 1–2 × 109 PFU per recombinant virus (Ad-GFP or Ad-FGF9) via the tail vein. Mice were fasted for 6 h and sacrificed for further analysis, 15 days after infection.

For AAV infection, mice were injected with 5x1011 vg of the AAV-shFGF9 or AAV-shCon via the tail vein, followed by feeding a Chow diet or HFD for 8 weeks. Then, mice were sacrificed for further analysis.

FGF9 Rosa26 knockin mice were generated by the insertion of FGF9 cDNA downstream of the Rosa26 promoter and a loxP-stop-loxP cassette at Beijing Biocytogen Co., Ltd., and Alb–Cre mice (express the Cre-recombinant gene under the control of the albumin gene promoter) were provided by Hongbing Zhang (Institute of Basic Medical Sciences, Peking Union Medical College), and then liver-specific FGF9 transgenic mice were obtained by crossing Alb–Cre mice to FGF9 Rosa26 knockin mice. FGF9 Rosa26 knockin mice were used as controls. All the mice were fed on a Chow diet or HFD for 3 months.

All the protocol related with animals was approved by the Animal Care and Use Committee of Tianjin Medical University (TMUaMEC) and conformed to criteria outlined in the National Institutes of Health (NIH; Bethesda, MD) Guide for the Care and Use of Laboratory Animals.

Culture of Mouse Primary Hepatocyte and Adeno-viral Infections

Briefly, 8-week-old male mice were anesthetized with bromethol and perfused with 0.5 mg/ml type II collagenase (Sigma-Aldrich) via the inferior vena cava to obtain hepatocytes as previously described (Wang et al., 2010). The cells were seeded at 6 well collagen-coated plates, and cultured with RPMI 1640 medium (H10394; Invitrogen) containing 10% (v/v) FBS (ExCell Bio, Shanghai, China), 50 units/ml penicillin and 50 μg/ml streptomycin (Penicillin–Streptomycin Solution, 100X, Solarbio Life Sciences, Beijing, China). After cell attachment for 4 h, a fresh medium was added after the unattached cells were washed away with PBS. For the adenovirus infection, primary hepatocytes were treated with 0.5 mM OA (CAS No. 112-80-1, Selleck) and 0.25 mM PA (CAS No. 57-10-3, Selleck) for 24 h before (Ad-shCon and Ad-shFGF9, MOI = 100) or after (Ad-GFP and Ad-FGF9, MOI = 100) adenovirus particle infection for 12 h.

Triglyceride Content

Liver tissue of 100 mg was homogenized in 1 ml of 5% Nonidet P-40 dissolved in water, heated to 95°C for 5 min, centrifuged for 2 min at 13,000×g. A fluorometric assay kit was used to measure triglyceride levels according to the manufacturer’s guidelines (Applygen Technologies, Inc., Beijing, China). Finally, the levels of triglyceride levels were normalized to the weight of liver and expressed as mg of triglyceride/g of tissue weight.

AAV-shRNA Viral Production and Purification

For the FGF9 knockdown studies, AAV gene delivery vectors were constructed by cloning FGF9 shRNA sequences into an AAV-shRNA-Ctrl plasmid (Addgene #85741, Watertown, MA), and AAV-shRNA-Ctrl encoding a nontargeting shRNA, was used as a control virus (AAV-shCon). For AAV-shFGF9, we generated the shRNA that would target FGF9 by using the Dharmacon siDESIGN center (http://www.dharmacon.com) as described (Yu et al., 2002), the antisense-loop-sense oligonucleotides synthesized, annealed, and subcloned into the Bbs1 and Xba1 sites of the AAV-shRNA-Ctrl plasmid. The AAV2/8 virus was generated by transfecting HEK-293T cells with pAAV2 insert containing either shRNA control or shRNA-FGF9 under the control of the mouse U6 promoter, pAAV2/8 (Addgene #112864, Watertown, MA) packaging plasmid expressing Rep/Cap genes, and pAdDeltaF6 (#112867).

The three plasmids were used for viral production with a triple-transfection, and the virus was purified according to the modified published methods (Challis et al., 2019). Briefly, triple plasmids were co-transfected to HEK-293T cells, and the cell culture medium was harvested at 72, 96, and 120 h. After purification by an iodixanol step gradient, the fraction containing the virus was desalted on 100 K concentrators with PBS as the diluent. AAV titers were determined by qPCR using primers targeting CMV. Each virus titer was calculated in genomes/ml with AAV-shRNA-Ctrl Luciferase at 2.4×1013 vg/reverse transcriptase reaction.
ml, AAV-shFGF9 at 2.6×10^{13} vg/ml. The viruses were aliquoted into siliconized tubes and stored at −80°C.

The primers used for constructing AAV-shFGF9 are as follows:

\text{shRNA FGF9 F: 5′-GATCCGGAGAACGTGATTTCATT TGTTCAGAGACTAAATGAAATCCAGTCTCGTCTTCCTCGAG-3′;}

\text{shRNA FGF9 R: 5′-AATTCTCGAGAAAAAGGAGGAG TGGATTCTATTAGTCTCTGTGAATCAAATGAAAATCCAGT CCTGCG-3′;}

Recombinant Adenovirus Production and Purification

Adenoviruses expressing FGF9 was prepared as previously described (Luo et al., 2007). Briefly, the full-length mouse FGF9 gene was first cloned into the pAd-Track-CMV shuttle vector. The resultant plasmid was linearized by digesting with restriction endonuclease PmeI and subsequently transformed into competent cells, which were transfected with Adenoviral backbone plasmid. Overall, the con
tamination and recombination was confirmed by restriction endonuclease analyses. Brie
tly, the sections were deparaffinized and rehydrated in distilled water, followed by staining. Finally, the samples were dehydrated, cleared, and mounted, followed by imaging using light microscopy.

Western Blotting Analysis

The homogenate of liver tissue or cells was prepared in lysis buffer (20 mM Tris–Cl pH7.5, 140 mM NaCl, 1 mM CaCl2 and MgCl2, 10 mM NaF, 1% NP-40, 10% glycerol, 2 mM Na-Vanadate, and 1 mM PMSF) supplemented with complete Protease Inhibitor Cocktail (cOmplete™, Sigma-Aldrich, Dallas, TX) for 30 min, centrifuged at 12,000 rpm at 4°C for 15 min. The protein samples were resolved by SDS-polyacrylamide gel electrophoresis and electrophoretically transferred to PVDF membranes. The membranes were blocked at room temperature for 2 h in 5% defatted milk dissolved in TBST (10 mM Tris–HCl, pH 7.4, and 150 mM NaCl), incubated at 4°C for overnight with the following antibodies: PPARγ (#AF6284, Affinity, 1:1000), FGF9 (#A6374, ABclonal, 1:500, and #ab206408, Abcam, 1:500), ChREBP antibodies: PPARγ (1:500), FGF9 (1:1000), ABclonal, 1:500, and #ab206408, Abcam, 1:500), ChREBP

STATISTICAL ANALYSIS

The quantitative data are represented as the mean ± SEM. A two-tailed, unpaired Student’s t-test was used for the pairwise comparison of genotypes or treatments. 1-way ANOVA and 2-
way ANOVA were used when comparing 3 or more groups, as indicated in the figure legends. The graphs and analysis were performed using GraphPad Prism 7.0 software. p < 0.05 was considered statistically significant.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The animal study was reviewed and approved by the Animal Care and Use Committee of Tianjin Medical University.

**AUTHOR CONTRIBUTIONS**

YC and JZ designed research studies; FZ, LZ and JH conducted experiments; FZ and MZ analyzed data; and YC wrote the manuscript. YC is the guarantor of this work and had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (Grants 81825004 and 81730024), the National Key Research and Development Program of China (2018YFA0800601), and the Scientific and Technological Research Project of Xinjiang Production and Construction Corps (Grant 2021AB028).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.850128/full#supplementary-material

**Supplementary Table S1** | List of specific primers used for real-time quantitative PCR gene expression analysis.

**REFERENCES**

Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., and Maratos-Flier, E. (2007). Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARalpha and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States. *Cell Metab.* 5 (6), 426–437. doi:10.1016/j.cmet.2007.05.002

Beenken, A., and Mohammadi, M. (2009). The FGF Family: Biology, Pathophysiology and Therapy. *Nat. Rev. Drug Discov.* 8 (3), 235–253. doi:10.1038/nrd2792

Benhamed, F., Denechaud, P. D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., et al. (2012). The Lipogenic Transcription Factor ChREBP Dissociates Hepatic Steatosis from Insulin Resistance in Mice and Humans. *J. Clin. Invest.* 122 (6), 2176–2194. doi:10.1172/jci41636

Browning, J. D., and Horton, J. D. (2004). Molecular Mediators of Hepatic Steatosis and Liver Injury. *J. Clin. Invest.* 114 (2), 147–152. doi:10.1172/jci22422

Brunt, E. M. (2010). Pathology of Nonalcoholic Fatty Liver Disease. *Nat. Rev. Gastroenterol. Hepatol.* 7 (4), 195–203. doi:10.1038/nrgastro.2010.21

Challis, R. C., Ravindra Kumar, S., Chan, K. Y., Challis, C., Beadle, K., Jiang, M. J., et al. (2019). Systemic AAV Vectors for Widespread and Targeted Gene Delivery in Rodents. *Nat. Protoc.* 14 (2), 379–414. doi:10.1038/s41596-018-0097-3

Colvin, J. S., Green, R. P., Schmahl, J., Capel, B., and Ornitz, D. M. (2001). Male-to-female Sex Reversal in Mice Lacking Fibroblast Growth Factor 9. *Cell* 104 (6), 873–889. doi:10.1016/s0092-8674(01)00284-7

Degirolamo, C., Sbabò, C., and Moschetta, A. (2016). Therapeutic Potential of the Endocrine Fibroblast Growth Factors FGF19, FGF21 and FGF23. *Nat. Rev. Drug Discov.* 15 (1), 51–69. doi:10.1038/nrd.2015.9

Dentin, R., Benhamed, F., Hainault, I., Faureau, V., Foufelle, F., Dyck, J. R., et al. (2006). Liver-specific Inhibition of ChREBP Improves Hepatic Steatosis and Insulin Resistance in Ob/ob Mice. *Diabetes* 55 (8), 2159–2170. doi:10.2337/db06-0200

Diraison, F., Moulin, P., and Beylot, M. (2003). Contribution of Hepatic De Novo Lipogenesis and Reestertification of Plasma Non Esterified Fatty Acids to Plasma Triglyceride Synthesis during Non-alcoholic Fatty Liver Disease. *Diabetes Metab.* 29 (5), 478–485. doi:10.1016/s1262-3636(07)70061-7

Donnelly, K. L., Smith, C. L., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., and Parks, E. J. (2005). Sources of Fatty Acids Stored in Liver and Secreted via Lipoproteins in Patients with Nonalcoholic Fatty Liver Disease. *J. Clin. Invest.* 115 (5), 1343–1351. doi:10.1172/jci23621

Fabbrini, E., Mohammed, B. S., Magkos, F., Korotenblat, K. M., Patterson, B. W., and Klein, S. (2008). Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women with Nonalcoholic Fatty Liver Disease. *Gastroenterology* 134 (4), 424–431. doi:10.1053/j.gastro.2007.11.038

Hinds, T. D., Jr., Burns, K. A., Hosick, P. A., McBeth, L., Nestor-Kalinowski, A., Drummond, H. A., et al. (2016). Biliverdin Reductase A Attenuates Hepatic Steatosis by Inhibition of Glycogen Synthase Kinase (GSK) 3β Phosphorylation of Serine 73 of Peroxisome Proliferator-Activated Receptor (PPAR) α. *J. Biol. Chem.* 291 (48), 25179–25191. doi:10.1074/jbc.M116.731703

Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswaran, V., et al. (2007). Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21. *Cell Metab.* 5 (6), 415–425. doi:10.1016/j.cmet.2007.05.003

Iwata, J., Tung, L., Urita, M., Hacia, J. G., Pelikan, R., Suzuki, A., et al. (2012). Fibroblast Growth Factor 9 (FGF9)-Pituitary Homeobox 2 (PITX2) Pathway Mediates Transforming Growth Factor β (TGFβ) Signaling to Regulate Cell Proliferation in Patalal Mesenchyme during Mouse Palatogenesis. *J. Biol. Chem.* 287 (4), 2353–2363. doi:10.1074/jbc.M111.280974

Jois, T., and Sleeman, M. W. (2017). The Regulation and Role of Carbohydrate Response Element-Binding Protein in Metabolic Homeostasis and Disease. *J. Neuroendocrinol.* 29 (10). doi:10.1111/jne.12473

Lefebvre, P., Chinetti, G., Fruchtart, J. C., and Staels, B. (2006). Sorting Out the Roles of PPAR Alpha in Energy Metabolism and Vascular Homeostasis. *J. Clin. Invest.* 116 (3), 571–580. doi:10.1172/jci27989

Leone, T. C., Weinheimer, C. J., and Kelly, D. P. (1999). A Critical Role for the Peroxisome Proliferator-Activated Receptor Alpha (PPARα) in the Cellular Fasting Response: the PPARα-Null Mouse as a Model of Fatty Acid Oxidation Disorders. *Proc. Natl. Acad. Sci. U S A.* 96 (13), 7473–7478. doi:10.1073/pnas.96.13.7473

Luo, J., Deng, Z. L., Luo, X., Tang, N., Song, W. X., Chen, J., et al. (2007). A Protocol for Rapid Generation of Recombinant Adenoviruses Using the AdEasy System. *Nat. Protoc.* 2 (5), 1236–1247. doi:10.1038/nprot.2007.135

Matussev, K., Haluzík, M., Lambert, G., Yim, S. H., Gavrilova, O., Ward, J. M., et al. (2003). Liver-specific Disruption of PPARγamma in Leptin-Deficient Mice Improves Fatty Liver but Aggravates Diabetic Phenotypes. *J. Clin. Invest.* 111 (5), 737–747. doi:10.1172/jci12723

Meikle, P. J., and Summers, S. A. (2017). Sphingolipids and Phospholipids in Insulin Resistance and Related Metabolic Disorders. *Nat. Rev. Endocrinol.* 13 (2), 79–91. doi:10.1038/nrendo.2016.169
Zhao et al. Autocrine FGF9 Alleviates Hepatic Steatosis

Ritchie, M., Hanouneh, I. A., Noureddin, M., Rolph, T., and Alkhouri, N. (2020). Fibroblast Growth Factor (FGF)-21 Based Therapies: A Magic Bullet for Nonalcoholic Fatty Liver Disease (NAFLD)? Expert Opin. Investig. Drugs 29 (2), 197–204. doi:10.1080/13543784.2020.1718104

Rottman, Y., and Sanyal, A. J. (2017). Current and Upcoming Pharmacotherapy for Non-alcoholic Fatty Liver Disease. Gut 66 (1), 180–190. doi:10.1136/gutjnl-2016-312431

Shamsi, F., Xue, R., Huang, T. L., Lundh, M., Liu, Y., Leiria, L. O., et al. (2020). FGF6 and FGF9 Regulate UCP1 Expression Independent of Brown Adipogenesis. Nat. Commun. 11 (1), 1421. doi:10.1038/s41467-020-15055-9

Shen, L., Cui, A., Xue, Y., Cui, Y., Dong, X., Gao, Y., et al. (2014). Hepatic Differentiated Embryo-Chondrocyte-Expressed Gene 1 (Dec1) Inhibits Sterol Regulatory Element-Binding Protein-1c (Srebp-1c) Expression and Alleviates Fatty Liver Phenotype. J. Biol. Chem. 289 (34), 23332–23342. doi:10.1074/jbc.M113.526343

Sun, Y., Wang, R., Zhao, S., Li, W., Liu, W., Tang, L., et al. (2019). FGF9 Inhibits browning Program of white Adipocytes and Associates with Human Obesity. J. Mol. Endocrinol. 62 (2), 79–90. doi:10.1530/JME-18-0151

Tsai, S. J., Wu, M. H., Chen, H. M., Chuang, P. C., and Wing, L. Y. (2002). Fibroblast Growth Factor-9 Is an Endometrial Stromal Growth Factor. Endocrinology 143 (7), 2715–2721. doi:10.1210/endo.143.7.8900

Wang, R., Kong, X., Cui, A., Liu, X., Xiang, R., Yang, Y., et al. (2010). Sterol-regulatory-element-binding Protein 1c Mediates the Effect of Insulin on the Expression of Cidea in Mouse Hepatocytes. Biochem. J. 430 (2), 245–254. doi:10.1042/bj20100701

Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., et al. (2009). Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice. Diabetes 58 (1), 250–259. doi:10.2337/db08-0392

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhao, Zhang, Zhang, Huang, Zhang and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.